Company Number: 13805399

Analysis Date: 2025-07-29 18:50 UTC

Financial Health Assessment for UKTRANSMERIDIAN LTD

---

1. Financial Health Score: Grade D

Explanation:
UKTRANSMERIDIAN LTD’s financial indicators reflect a very fragile state, with net assets and shareholders' funds reported at just £1 consistently over three years. This minimal equity base indicates a company without substantive financial cushioning or capital, akin to a patient with extremely low vital signs and no reserves to withstand shocks. The absence of reported revenue, profits, or asset values signals a dormant or near-dormant financial condition, placing the company at high risk and limiting operational flexibility.

---

2. Key Vital Signs (Financial Metrics):

Metric	2023 Value	Interpretation
Net Assets	£1	Essentially no equity; critically low capital
Total Assets less Current Liabilities	£1	No meaningful assets to cover liabilities
Shareholders Funds	£1	No retained earnings; no buffer for losses
Number of Employees	2	Small workforce consistent with micro entity
Account Category	Micro	Small scale with minimal filing requirements
Filing Status	Up-to-date	Compliance with filings is a positive sign

Interpretation:
The “vital signs” indicate a company with negligible financial substance. The net asset figure of £1 is the bare minimum statutory capital, similar to a patient whose vital signs are barely registering. The company’s filings are current, which is positive, but the lack of financial growth or capital injection over multiple years suggests inactivity or minimal trading operations.

---

3. Diagnosis:

The financial data reveals UKTRANSMERIDIAN LTD is in a state of financial “near dormancy” or minimal activity. The company is maintaining its legal registration and filing obligations but shows no evidence of operational scale or financial growth. The balance sheet is essentially flat-lined at a nominal value, with no indication of trading profits, assets accumulation, or working capital. This can be symptomatic of:

• A company recently incorporated and yet to commence significant trading.
• A holding entity or shell with minimal transactions.
• A business in early development stages without investment or revenue.

The appointment of a new director in March 2023 may signal plans for revitalization; however, there are no financial indicators yet reflecting operational improvement.

---

4. Prognosis:

Without intervention or capital infusion, the company remains at high risk of financial distress if it plans to operate actively. Its current financial posture offers no buffer to absorb losses or fund expansion. However, compliance with filing deadlines and presence of two employees suggest a baseline operational structure is maintained. The prognosis hinges on whether the company can secure funding, generate revenue, or increase assets. Failure to do so will likely result in continued stagnation.

---

5. Recommendations:

• Capital Injection: Introduce additional equity or loans to strengthen the balance sheet and provide working capital—this is the equivalent of administering “life support” to stabilize the company’s financial health.
• Operational Activation: Develop and execute a clear business plan to generate revenue streams, improving cash flow “heartbeat” and sustaining staff and operations.
• Financial Monitoring: Implement regular financial reviews to track key metrics like cash flow, profit margins, and asset accumulation to detect early “symptoms” of distress or improvement.
• Cost Management: Keep overheads minimal until revenue streams are established, preserving the company’s financial reserves.
• Director Engagement: Leverage the new director’s expertise to steer company strategy actively and drive operational momentum.
• Explore Funding Options: Consider grants, loans, or investor funding appropriate for micro-entities to provide financial cushioning.

---